tbuckley/cabot-search huggingface dataset:
Encuesta EUVAC-NET: sistemas nacionales de vigilancia de la tos ferina en la Unión Europea, Suiza, Noruega e Islandia
Authors: J E Schmidt, A E Tozzi, L Rava, S Glismann
Journal: Eurosurveillance (2001)

Por medio de un cuestionario enviado por correo a los Estados Miembros de la Union Europea (UE), asi como a Suiza, Noruega e Islandia, se realizo una encuesta para conocer el tipo de informacion recogida sistematicamente por los sistemas nacionales de vigilancia de la tos ferina. Se solicitaron datos sobre metodos de vigilancia, tipo de informacion registrada de los casos de tos ferina, programa de vacunacion, tipo de vacuna utilizado y metodos de evaluacion de la cobertura vacunal. Se descubrieron grandes diferencias entre los metodos de vigilancia locales, las estrategias de vacunacion y los procedimientos empleados para calcular la cobertura vacunal en cada pais participante. Sin embargo, los resultados de la encuesta muestran la existencia de grupos de variables comunes en muchos paises. Las futuras actividades del proyecto EUVAC-NET consistiran en definir elementos homogeneos en los sistemas nacionales y en reagrupar de forma adecuada aquellos paises con caracteristicas similares de vigilancia.
A phase 1 study of selinexor (S) in combination with paclitaxel (P) and carboplatin (C) in patients (pts) with advanced ovarian (OC) or endometrial cancers (EC)
Authors: V. Makker, N. Boucicaut, K.A. Cadoo, R. Grisham, D.M. Hyman, R. O'Cearbhail, A. Snyder Charen, W. Tew, M. Martin, C. Aghajanian
Journal: Annals of Oncology (2017)
The impact of UGT1A1 genetic polymorphism on safety in unresectable pancreatic cancer patients receiving FOLFIRINOX therapy: A subset analysis of JASPAC 06 study
Authors: H. Shirasu, K. Omae, H. Fujii, N. Mizuno, M. Ozaka, H. Ueno, S. Kobayashi, K. Uesugi, N. Kobayashi, H. Hayashi, K. Sudo, N. Okano, Y. Horita, K. Kamei, Y. Seigo, H. Takafumi, T. Henmi, M. Kobayashi, A. Todaka, A. Fukutomi
Journal: Annals of Oncology (2017)
Biomimetic albumin-modified gold nanorods for photothermo-chemotherapy and macrophage polarization modulation
Authors: Dongdong Li, Meng Zhang, Fan Xu, Yingzhi Chen, Binfan Chen, Ya Chang, Huihai Zhong, Hongyue Jin, Yongzhuo Huang
Journal: Acta Pharmaceutica Sinica B (2017)

Nanotechnology-based photothermal therapy has attracted great attention in the past decade. Nevertheless, photothermal therapy has some inherent drawbacks, such as the uneven heat production and limited laser penetration, often leading to insufficient treatment outcomes. Here, we developed a combination strategy to improve cancer therapy. The biomimetic albumin-modified gold nanorods (AuNRs) were prepared with incorporation of paclitaxel (PTX). This therapeutic system was characterized by several features. First, the albumin modification enhanced the biocompatibility and colloidal stability. Second, the surface-coated albumin promoted cellular uptake via the albumin-binding protein pathway. Third, PTX was incorporated via hydrophobic interaction between PTX and the albumin lipophilic domain. Fourth, the system can be used for combined photothermo-chemotherapy for yielding synergistic effects. The antitumor activity of the system was evaluated both in vitro and in vivo using the HCT116 colon cancer cell and tumor model. The combination therapy was found with an enhanced treatment efficiency and no obvious side effect. Most importantly, the thermal effect was also discovered with the ability to modulate the tumor microenvironments and suppress the macrophages polarization towards the M2 pro-tumor phenotype. It could be a mechanism for photothermal immunotherapy. The combination strategy and the system provide a potential method for cancer therapy.
Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
Authors: Courtney Davis, Huseyin Naci, Evrim Gurpinar, Elita Poplavska, Ashlyn Pinto, Ajay Aggarwal
Journal: BMJ (2017)

<b>Objective</b>&nbsp;To determine the availability of data on overall survival and quality of life benefits of cancer drugs approved in Europe. <b>Design</b>&nbsp;Retrospective cohort study. <b>Setting</b>&nbsp;Publicly accessible regulatory and scientific reports on cancer approvals by the European Medicines Agency (EMA) from 2009 to 2013. <b>Main outcome measures</b>&nbsp;Pivotal and postmarketing trials of cancer drugs according to their design features (randomisation, crossover, blinding), comparators, and endpoints. Availability and magnitude of benefit on overall survival or quality of life determined at time of approval and after market entry. Validated European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS) used to assess the clinical value of the reported gains in published studies of cancer drugs. <b>Results</b>&nbsp;From 2009 to 2013, the EMA approved the use of 48 cancer drugs for 68 indications. Of these, eight indications (12%) were approved on the basis of a single arm study. At the time of market approval, there was significant prolongation of survival in 24 of the 68 (35%). The magnitude of the benefit on overall survival ranged from 1.0 to 5.8 months (median 2.7 months). At the time of market approval, there was an improvement in quality of life in seven of 68 indications (10%). Out of 44 indications for which there was no evidence of a survival gain at the time of market authorisation, in the subsequent postmarketing period there was evidence for extension of life in three (7%) and reported benefit on quality of life in five (11%). Of the 68 cancer indications with EMA approval, and with a median of 5.4 years' follow-up (minimum 3.3 years, maximum 8.1 years), only 35 (51%) had shown a significant improvement in survival or quality of life, while 33 (49%) remained uncertain. Of 23 indications associated with a survival benefit that could be scored with the ESMO-MCBS tool, the benefit was judged to be clinically meaningful in less than half (11/23, 48%). <b>Conclusions</b>&nbsp;This systematic evaluation of oncology approvals by the EMA in 2009-13 shows that most drugs entered the market without evidence of benefit on survival or quality of life. At a minimum of 3.3 years after market entry, there was still no conclusive evidence that these drugs either extended or improved life for most cancer indications. When there were survival gains over existing treatment options or placebo, they were often marginal.
Abstract 20249: Microparticles From Systemic Sclerosis Patients May Affect Vascular Inflammation of Endothelial Cells In Vitro
Authors: Matthew R Lammi, Samuel Okpechi, Dorota Wyczechowska, Lesley A Saketkoo, Natalie Bauer, Kusma Pyakurel, Abdelmetalab Tarhuni, Bennett deBoisblanc, A. H Boulares
Journal: Circulation (2016)

Introduction: Microparticles (MPs) are submicron vesicles released from cells both in health and in response to inflammation, apoptosis, or shear stress. Prior investigations have suggested that MP...
Safety and efficacy of pazopanib (PAZ) in advanced soft tissue carcinoma (aSTS) by prior lines of therapy, age, and dose modifications: PALETTE subgroup analyses
Authors: A. Le Cesne, S. Bauer, G.D.S. Demetri, W.T.A. van der Graaf, G. Han, L. Dezzani, Q. Ahmad, H. Gelderblom
Journal: Annals of Oncology (2017)
Local Adjuvant Treatment with Low-Dose CpG-B Offers Durable Protection against Disease Recurrence in Clinical Stage I–II Melanoma: Data from Two Randomized Phase II Trials
Authors: Bas D. Koster, Mari F.C.M. van den Hout, Berbel J.R. Sluijter, Barbara G. Molenkamp, Ronald J.C.L.M. Vuylsteke, Arnold Baars, Paul A.M. van Leeuwen, Rik J. Scheper, M. Petrousjka van den Tol, Alfons J.M. van den Eertwegh, Tanja D. de Gruijl
Journal: Clinical Cancer Research (2017)

Abstract Purpose: Although risk of recurrence after surgical removal of clinical stage I–II melanoma is considerable, there is no adjuvant therapy with proven efficacy. Here, we provide clinical evidence that a local conditioning regimen, aimed at immunologic arming of the tumor-draining lymph nodes, may provide durable protection against disease recurrence (median follow-up, 88.8 months). Experimental Design: In two randomized phase II trials, patients, diagnosed with stage I–II melanoma after excision of the primary tumor, received local injections at the primary tumor excision site within 7 days preceding re-excision and sentinel lymph node (SLN) biopsy of either a saline placebo (n = 22) or low-dose CpG type B (CpG-B) with (n = 9) or without (n = 21) low-dose GM-CSF. Results: CpG-B treatment was shown to be safe, to boost locoregional and systemic immunity, to be associated with lower rates of tumor-involved SLN (10% vs. 36% in controls, P = 0.04), and, at a median follow-up of 88.8 months, to profoundly improve recurrence-free survival (P = 0.008), even for patients with histologically confirmed (i.e., pathologic) stage I–II disease (P = 0.02). Conclusions: Potentially offering durable protection, local low-dose CpG-B administration in early-stage melanoma provides an adjuvant treatment option for a large group of patients currently going untreated despite being at considerable risk for disease recurrence. Once validated in a larger randomized phase III trial, this nontoxic immunopotentiating regimen may prove clinically transformative. Clin Cancer Res; 23(19); 5679–86. ©2017 AACR.
EGFR T790M resistance mutation in NSCLC: Real-life data of patients treated with osimertinib.
Authors: Maximilian J. Hochmair, Sophia Holzer, Martin Filipits, Andrea Mohn-Staudner, Madeleine Arns, Peter Errhalt, Gudrun Absenger, Ursula Koller-Herzog, Ulrike Setinek, Ferdinand Haslbauer, Mark A. Korger, Kurt Patocka, Rainer Kolb, Otto Burghuber
Journal: Journal of Clinical Oncology (2016)

e20572 Background: The EGFR T790M resistance mutation located on Exon 20 is the most common mechanism of drug resistance to EGFR tyrosine kinase inhibitors (TKI). The mutation can be detected by re-biopsy as well liquid biopsy. Osimertinib, a third generation EGFR-TKI, showed a highly clinical activity in these patients. We report about our experience with Osimertinib in EGFR-mutated NSCLC patients, who became resistant to first or second generation TKI's due to EGFR T790M mutation. Methods: From April to November 2015 we administered osimertinib 80 mg daily to 30 patients who had disease progression after previous treatment with an EFGR TKI. Astra Zeneca provided osimertinib for these patients who had no further treatment options for named patient use. The T790M mutation status was assessed by re-biopsy and/or liquid biopsy. For liquid biopsies, blood samples were collected in EDTA-containing vacutainer tubes and processed within 2 hours after collection. Cell-free plasma DNA was extracted by using the QIAamp circulating nucleic acid kit (Qiagen) according to the manufacturer’s instructions. Mutation status was assessed with QX-100 Droplet Digital PCR System (Bio-Rad). Results: The T790M mutation status was assessed in 12 patients by liquid biopsy only and in 2 by re-biopsy of the tumor. In 16 the T790M mutation was detected by both methods. 28 (93%) showed a clear clinical and radiographic response. Out of these 7 reached a complete remission (23%), 21 showed partial response (70%). In 2 stable disease (7%) after treatment with osimertinib was observed. 4 had initial symptomatic brain metastasis, without any further option of local treatment, and showed a partial remission radiographically and a clear clinical benefit intracerebral. Osimertinib was well tolerated. No clinically relevant significant side effects were reported. Conclusions: Osimertinib was highly active in our patients, while showing good safety profile. Therefore, re-biopsy or liquid biopsy should be performed in clinical routine to detect the T790M mutation. With the above described method, liquid biopsy could replace re-biopsy in clinical practice in the future.
Abstract 14454: Inhaled Epoprostenol is Equivalent to Inhaled Nitric Oxide for Right Ventricular Failure Following Left Ventricular Assist Device Placement
Authors: Sanford Zeigler, Charles Hill, Yasuhiro Shudo, Hanjay Wang, Y. Joseph Woo, Dipanjan Banerjee, Richard Ha
Journal: Circulation (2016)

Introduction: Right ventricular failure following left ventricular assist device placement increases morbidity and mortality. Inhaled pulmonary vasodilators are frequently used to prevent and treat...
Leptospirose em Portugal: epidemiologia de 1991 a 1997
Authors: J M Falcão, P J Nogueira, C MatiasDias, Z. P. Pimenta
Journal: Eurosurveillance (1999)

O termo leptospirose descreve um grupo de doencas provocadas por membros da ordem Spirochaetales, principalmente a especie Leptospira interrogans. A infeccao pode ser assintomatica, mas a doenca pode ocorrer com gravidade e caracteristicas clinicas diferentes (frequentemente sugestivas de meningite, encefalite ou gripe). A duracao da leptospirose varia de alguns dias a varias semanas, de acordo com a gravidade e o tratamento. A fatalidade dos casos e baixa, mas pode ultrapassar os 20% nos doentes que desenvolvem insuficiencia hepatica e renal (doenca de Weil) e nos individuos idosos.
Prognostic value of master transcriptional regulators (MTRs) in early stage breast cancer
Authors: S. Barron, K. Jirström, B. Nodin, H. Jernström, C. Ingvar, B. Moran, C-J.A. Wang, T. Loughman, B. Fender, P. Dynoodt, C. Lopez-Ruiz, W. Gallagher
Journal: Annals of Oncology (2017)
Intracranial efficacy of first-line crizotinib vs. chemotherapy in ALK-positive NSCLC
Authors: B Solomon, F Cappuzzo, E Felip, Fiona H Blackhall, D Costa, D Kim, K Nakagawa, Y Wu, T Mekhail, J Paolini, J Tursi, T Usari, K Wilner, P Selaru, T Mok
Journal: Journal of Thoracic Oncology (2015)
Expanded Access for Nusinersen in Patients With Spinal Muscular Atropy: Negotiating Limited Data, Limited Alternative Treatments, and Limited Hospital Resources
Authors: Benjamin S. Wilfond, Christian Morales, Holly A. Taylor
Journal: The American Journal of Bioethics (2017)

"Expanded Access for Nusinersen in Patients With Spinal Muscular Atropy: Negotiating Limited Data, Limited Alternative Treatments, and Limited Hospital Resources." The American Journal of Bioethics, 17(10), pp. 66–67
Topography of Tumor Mutational Burden (TMB) and Immune-related Genomic Alterations (GA) Across Gastrointestinal Malignancies (GIm): A Study of 22,570 Cases
Authors: S.J. Klempner, G.M. Frampton, J. Chao, M. Bailey, P. Stephens, J.S. Ross, V.A. Miller, S.M. Ali, A.B. Schrock
Journal: Annals of Oncology (2017)
Portal vein infiltration in patients with hepatocellular carcinoma: The relevance of correct classification.
Authors: Arndt Weinmann, Verena Steinle, Sandra Koch, Daniel Pinto dos Santos, Jens Uwe Marquardt, Martin Sprinzl, Hauke Lang, Christoph Düber, Peter R. Galle, Marcus A. Woerns, Roman Kloeckner
Journal: Journal of Clinical Oncology (2017)

e15651 Background: Portal vein invasion (PVI) is has a significant impact on the prognosis of patients with hepatocellular carcinoma (HCC). Patients with PVI are classified as stage C in the BCLC score and systemic therapy is recommended. Patients with minor PVI are frequently misclassified due to radiological challenges in determining malignant PVI or non-adherence to guidelines. The concept of resection or TACE in limited PVI is sometimes followed with the assumption of a negligible influence on survival. Aim of this study is the reevaluation of PVI and the analysis of the impact of a misclassification. Methods: 763 patients with HCC of a total of 1413 were extracted from the clinical registry of our tertiary center as an ongoing effort to reevaluate the extent of PVI in all patients treated between 1/1/2000 and 12/31/2015. PVI was diagnosed by re-evaluating all available CT or MRI scans by an experienced liver imaging radiologist. PVI was documented using the Liver Cancer Study Group of Japan classification ranging from Vp0-Vp4: Vp0 = no PVI; Vp1 = segmental; Vp2 = right anterior or posterior PV; Vp3 = right or left PV; Vp4 = main trunk. The influence on survival was calculated for each BCLC stage. Results: 259 patients (pat) were classified with PVI. Median age at diagnosis was 65.3 years, 213 patients (82.2%) were male. Etiology of liver disease was alcohol (43.6%), viral hepatitis (29.8%), NASH (5.8%), and others (10.4%). No liver disease was present in 18 pat (6.9%). No liver cirrhosis (LCI) was present in 32 pat (12.4%). LCI was classified as Child Pugh stage A/B/C in 65 (25.1%)/109 (42.1%) and 52 (20.1%) of patients. BCLC classification prior to reevaluation in pat with new PVI was A/B/C/D in 9/13/164/71 of cases. Comparing the overall survival (OS) of pat initially classified as BCLC A with or without PVI was 21.3 months vs. 106.4 months (p = 0.001), in BCLC B the OS was 11.0 months vs. 37.7 months (p = 0.001). Conclusions: Even minor PVI leads to dismal prognosis. Meticulous evaluation of cross sectional imaging is crucial for the clinical management of patients with HCC. Once PVI has been diagnosed, such patients have to be classified as advanced stage. The guidelines should be followed closely, irrespective of the extent of PVI.
ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis
Authors: A.R. Clamp, I. McNeish, A. Dean, D. Gallardo, J. Weon-Kim, D. O'Donnell, J. Hook, C. Coyle, S.P. Blagden, J. Brenton, R. Naik, T. Perren, S. Sundar, A. Cook, E. James, A.M. Swart, S. Stenning, R. Kaplan, J. Ledermann
Journal: Annals of Oncology (2017)
Efficacy and safety of palbociclib in patients with advanced gastrointestinal stromal tumors refractory to imatinib and sunitinib
Authors: A. Italiano, A. Adenis, J-Y. Blay, F. Duffaud, M. Rios, E. Bompas, O. Bouche, M. Pulido, A. Le Cesne
Journal: Annals of Oncology (2017)
Ceria nanocrystals decorated mesoporous silica nanoparticle based ROS-scavenging tissue adhesive for highly efficient regenerative wound healing
Authors: Haibin Wu, Fangyuan Li, Shuaifei Wang, Jingxiong Lu, Jinquan Li, Yang Du, Xiaolian Sun, Xiaoyuan Chen, Jianqing Gao, Daishun Ling
Journal: Biomaterials (2017)
Studies on the Purification and Properties of the Rabbit-Papilloma-Virus-Protein&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;
Authors: W. Ray Bryan, J. W. Beard
Journal: JNCI Journal of the National Cancer Institute (1941)

Studies on the Purification and Properties of the Rabbit-Papilloma-Virus-Protein Get access W. Ray Bryan, W. Ray Bryan research fellow National Cancer Institute, National Institute of Health, United States Public Health Service Search for other works by this author on: Oxford Academic PubMed Google Scholar J. W. Beard J. W. Beard assistant professor of surgery, in charge of experimental surgery Department of Surgery, Duke University School of Medicine Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 1, Issue 5, April 1941, Pages 607–673, https://doi.org/10.1093/jnci/1.5.607 Published: 01 April 1941
Role of induction chemotherapy in locally advanced T4b oral cavity cancers: A single Institute experience
Authors: K.N. Lokesh, T. Chaudhuri, K.C. Lakshmaiah, G. Babu, D. Lokanatha, L.A. Jacob, S. Babu, A. Rudresha, L. Rajeev
Journal: Annals of Oncology (2017)
Combination of the VEGF receptor tyrosine kinase sunitinib and the mTOR inhibitor rapamycin leads to tumor regression in the RENCA model
Authors: Hans Hammers, Silvia Paesante, Li Shen, Michelle Rudek, Roberto Pili
Journal: Cancer Research (2008)

1104  Introduction: Tyrosine kinase inhibitors such as sunitinib targeting angiogenesis via the vascular endothelial growth factor (VEGF) pathway, as well as mTOR inhibitors have changed the medical management of metastatic renal cell carcinoma. mTOR inhibitors have multiple effects including the downregulation of hypoxia-inducible factor 1 alpha (HIF-1alpha), a key regulator of angiogenesis. Thus, we hypothesized that the combination of sunitinib and rapamycin has a greater inhibitory effect in a murine renal cell carcinoma model as compared to single agents. Methods: We utilized the RENCA cells, an aggressive syngeneic murine renal cell carcinoma, in a prevention and intervention model. Tumor weight was the primary endpoint. Microvascular density, apoptosis, proliferation, hypoxia and fibrin deposition was determined by cardiac perfusion with thick sectioning and confocal analysis. Direct effect on tumor cell growth was determined by proliferation assay in vitro. Plasma levels of rapamycin and sunitinib were obtained. In vivo studies with an orthotopic xenograft model are ongoing. Results: In vitro, sunitinib had no direct growth inhibitory effect, but enhanced the inhibitory effect seen with rapamycin. In the prevention model both, sunitinib and rapamycin, lead to a significant tumor growth inhibition (> 90%) as single agents. In the combination group, no tumor mass could be appreciated macroscopically, but a scant rim of tumor cells was seen on tissue section. In the intervention study tumors were allowed to reach a mass of 1 gram before treatment was initiated. In this setting, single agents were less effective when compared to the prevention trial, but the combination of these agents lead to tumor regression. Histological analyses demonstrated decreased microvascular density in the sunitinib as well as in the combination treated tumors. Apoptosis was increased in all treatment groups. The treatment with rapamycin induced a significant intratumoral hemorrhage. No thrombocytopenia or platelet dysfunction was observed. Drug levels of rapamycin and sunitinib were in a plasma achievable range. Conclusion: The combination of sunitinib and rapamycin lead to an unprecedented tumor regression and further mechanistic and clinical investigations are warranted
Authors’ reply: HIV-1 outbreak among injecting drug users in Greece, 2011: a preliminary report
Authors: A Hatzakis, D Paraskevis, J Kremastinou, M Malliori
Journal: Eurosurveillance (2011)

Preview this article: Authors’ reply: HIV-1 outbreak among injecting drug users in Greece, 2011: a preliminary report, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/16/41/art19987-en-1.gif
Myeloid-derived suppressor cells are associated with a decrease of tumor antigen-specific Th1 immunity in non-small cell lung cancer
Authors: O. Adotevi, E. Lauret Marie Joseph, C. Laheurte, M. Dosset, E. Fabre-Guillevin, P. Jacoulet, G. Eberts, G. Helluin, L. Boullerot, L. Rangan, Y. Godet, V. Westeel
Journal: Annals of Oncology (2017)
Pandemic influenza A(H1N1)v in New Zealand: the experience from April to August 2009
Authors: M G Baker, N Wilson, Q S Huang, S Paine, L Lopez, D Bandaranayake, M Tobias, K Mason, G F Mackereth, M Jacobs, C Thornley, S Roberts, C McArthur
Journal: Eurosurveillance (2009)

Binary file ES_Abstracts_Final_ECDC.txt matches
Nab-paclitaxel (Nab-P) in HER2-ve advanced breast cancer (ABC) patients (pts): From randomized trials to real-life setting: Results from GIM13 - AMBRA study
Authors: G. Mustacchi, M. Cazzaniga, E. Bria, G. Bisagni, L. Biganzoli, P. Pronzato, S. De Placido, E. Romagnoli, F. Montemurro, P. Marchetti, M. De Laurentiis, F. Riccardi, A. Turletti, A. Michelotti, C. Natoli, L. Livi, L. Del Mastro, M. Donadio, O. Garrone, M. Giordano
Journal: Annals of Oncology (2017)
GW28-e1169 Impact of the Incidence of Contrast Induced Acute Kidney Injury for Coronary Artery Disease in Diabetes Patients with Percutaneous Coronary Intervention more than once during short periods of Injection of Contrast Medium
Authors: Xin Zhao, Yanjie Liu, Yaling Han, Chonghuai Gu, Xiaozeng Wang, Wang Shuang
Journal: Journal of the American College of Cardiology (2017)
IMpassion131: Phase III study comparing 1L atezolizumab with paclitaxel vs placebo with paclitaxel in treatment-naive patients with inoperable locally advanced or metastatic triple negative breast cancer (mTNBC)
Authors: D. Miles, F. Andre, J. Gligorov, S. Verma, B. Xu, D. Cameron, C.H. Barrios, A. Schneeweiss, V. Easton, I. Dolado, J. O'Shaughnessy
Journal: Annals of Oncology (2017)